Hasil Pencarian - Jens Hillengass

Perbaiki Hasil
  1. 1
    Diffusion-Weighted MRI—The Way Forward for MRI in Myeloma?

    Diffusion-Weighted MRI—The Way Forward for MRI in Myeloma? oleh Jens Hillengass, Maximilian Merz, Ronald Alberico, Majid Chalian

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma

    The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma oleh Jo Caers, Nadia Withofs, Jens Hillengass, Paolo Simoni, Elena Zamagni, Roland Hustinx, Yves Beguin

    Diterbitkan 2014-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation

    Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation oleh Jennifer Mosebach, Sofia Shah, Stefan Delorme, Thomas Hielscher, Hartmut Goldschmidt, Heinz-Peter Schlemmer, Stefan Schönland, Ute Hegenbart, Jens Hillengass

    Diterbitkan 2018-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma

    Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma oleh Jens Hillengass, Sofia Ayyaz, Kerstin Kilk, Marc-André Weber, Thomas Hielscher, Rajiv Shah, Dirk Hose, Stefan Delorme, Hartmut Goldschmidt, Kai Neben

    Diterbitkan 2012-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma

    Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma oleh Christos Sachpekidis, Maximilian Merz, Annette Kopp-Schneider, Anna Jauch, Marc-Steffen Raab, Sandra Sauer, Jens Hillengass, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss

    Diterbitkan 2019-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance

    CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance oleh Anja Seckinger, Jens Hillengass, Martina Emde, Susanne Beck, Christoph Kimmich, Tobias Dittrich, Michael Hundemer, Anna Jauch, Ute Hegenbart, Marc-Steffen Raab, Anthony D. Ho, Stefan Schönland, Dirk Hose

    Diterbitkan 2018-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

    Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients underg... oleh Kai Neben, Anna Jauch, Uta Bertsch, Christiane Heiss, Thomas Hielscher, Anja Seckinger, Tina Mors, Nadine Zoe Müller, Jens Hillengass, Marc S. Raab, Anthony D. Ho, Dirk Hose, Hartmut Goldschmidt

    Diterbitkan 2010-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma

    A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma oleh Elias K. Mai, Thomas Hielscher, Jost K. Kloth, Maximilian Merz, Sofia Shah, Marc S. Raab, Michaela Hillengass, Barbara Wagner, Anna Jauch, Dirk Hose, Marc-André Weber, Stefan Delorme, Hartmut Goldschmidt, Jens Hillengass

    Diterbitkan 2015-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

    Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma oleh Niels Weinhold, Desiree Kirn, Anja Seckinger, Thomas Hielscher, Martin Granzow, Uta Bertsch, Gerlinde Egerer, Hans Salwender, Igor W. Blau, Katja Weisel, Jens Hillengass, Marc S. Raab, Dirk Hose, Hartmut Goldschmidt, Anna Jauch

    Diterbitkan 2016-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    P831: NOVEL IMMUNOSUPPRESSIVE MYELOID POPULATIONS IN THE BONE MARROW (BM) AND OSTEOLYTIC LESIONS (OL) OF MULTIPLE MYELOMA (MM) PATIENTS

    P831: NOVEL IMMUNOSUPPRESSIVE MYELOID POPULATIONS IN THE BONE MARROW (BM) AND OSTEOLYTIC LESIONS (OL) OF MULTIPLE MYELOMA (MM) PATIENTS oleh Jens Hillengass, Romain Lannes, Saeed Daneshmandi, Cameron Macdonald, Qi Yan, Jeeeun Choi, Prashant Singh, Ahmed Belal, Ronald Alberico, Ian Lund, Megan Schaefer, Sarah Parker, Nikhil Munshi, Kenneth Anderson, Mehmet Samur, Philip Mccarthy, Hemn Mohammadpour

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

    The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma oleh Mohamed H. S. Awwad, Katharina Kriegsmann, Julian Plaumann, Michael Benn, Jens Hillengass, Marc S. Raab, Uta Bertsch, Markus Munder, Katja Weisel, Hans Jürgen Salwender, Mathias Hänel, Roland Fenk, Jan Dürig, Carsten Müller-Tidow, Hartmut Goldschmidt, Michael Hundemer

    Diterbitkan 2018-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Changes in Bone Marrow Fat upon Dietary-Induced Weight Loss

    Changes in Bone Marrow Fat upon Dietary-Induced Weight Loss oleh Manuela Spurny, Yixin Jiang, Solomon A. Sowah, Ruth Schübel, Tobias Nonnenmacher, Robert Bertheau, Romy Kirsten, Theron Johnson, Jens Hillengass, Christopher L. Schlett, Oyunbileg von Stackelberg, Cornelia M. Ulrich, Rudolf Kaaks, Hans-Ulrich Kauczor, Tilman Kühn, Johanna Nattenmüller

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

    Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma oleh Dirk Hose, Thierry Rème, Thomas Hielscher, Jérôme Moreaux, Tobias Messner, Anja Seckinger, Axel Benner, John D. Shaughnessy, Bart Barlogie, Yiming Zhou, Jens Hillengass, Uta Bertsch, Kai Neben, Thomas Möhler, Jean François Rossi, Anna Jauch, Bernard Klein, Hartmut Goldschmidt

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

    Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee oleh Shaji Kumar, Lawrence Baizer, Natalie S. Callander, Sergio A. Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul G. Richardson, Elena I. Schwartz, Anthony Reiman, Suzanne Lentzsch, Philip L. McCarthy, Sundar Jagannath, Andrew J. Yee, Richard F. Little, Noopur S. Raje

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

    Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial oleh Martin Kropff, Honorata Giongco Baylon, Jens Hillengass, Tadeusz Robak, Roman Hajek, Peter Liebisch, Stefan Goranov, Cyrille Hulin, Joan Bladé, Tommaso Caravita, Herve Avet-Loiseau, Thomas M. Moehler, Claire Pattou, Lela Lucy, Elisabeth Kueenburg, Axel Glasmacher, Robert Zerbib, Thierry Facon

    Diterbitkan 2012-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

    Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation oleh Maximilian Merz, Anna Jauch, Thomas Hielscher, Elias K. Mai, Anja Seckinger, Dirk Hose, Uta Bertsch, Kai Neben, Marc S. Raab, Hans Salwender, Igor W. Blau, Hans-Walter Lindemann, Ingo Schmidt-Wolf, Christof Scheid, Mathias Haenel, Katja Weisel, Hartmut Goldschmidt, Jens Hillengass

    Diterbitkan 2017-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

    Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma oleh Maximilian Merz, Anna Jauch, Thomas Hielscher, Tilmann Bochtler, Stefan Olaf Schönland, Anja Seckinger, Dirk Hose, Uta Bertsch, Kai Neben, Marc Steffen Raab, Jens Hillengass, Hans Salwender, Igor Wolfgang Blau, Hans-Walter Lindemann, Ingo G.H. Schmidt-Wolf, Christof Scheid, Mathias Haenel, Katja C. Weisel, Hartmut Goldschmidt

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

    Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial oleh Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Peter Brossart, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt

    Diterbitkan 2016-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma

    Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma oleh David C. Johnson, Niels Weinhold, Jonathan S. Mitchell, Bowang Chen, Martin Kaiser, Dil B. Begum, Jens Hillengass, Uta Bertsch, Walter A. Gregory, David Cairns, Graham H. Jackson, Asta Försti, Jolanta Nickel, Per Hoffmann, Markus M. Nöethen, Owen W. Stephens, Bart Barlogie, Faith E. Davis, Kari Hemminki, Hartmut Goldschmidt, Richard S. Houlston, Gareth J. Morgan

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

    Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial oleh Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Ingo G.H. Schmidt-Wolf, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt

    Diterbitkan 2015-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: